[go: up one dir, main page]

SA517380842B1 - بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام - Google Patents

بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام

Info

Publication number
SA517380842B1
SA517380842B1 SA517380842A SA517380842A SA517380842B1 SA 517380842 B1 SA517380842 B1 SA 517380842B1 SA 517380842 A SA517380842 A SA 517380842A SA 517380842 A SA517380842 A SA 517380842A SA 517380842 B1 SA517380842 B1 SA 517380842B1
Authority
SA
Saudi Arabia
Prior art keywords
interleukin
polypeptide
fusion protein
receptor alpha
methods
Prior art date
Application number
SA517380842A
Other languages
English (en)
Inventor
توماس ماليك
Original Assignee
يونيفيرستى اوف ميامى
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA517380842(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by يونيفيرستى اوف ميامى filed Critical يونيفيرستى اوف ميامى
Publication of SA517380842B1 publication Critical patent/SA517380842B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

تم تقديم العديد من الطرق والتركيبات التي يمكن استخدامها من أجل تضمين النظام المناعي immune system. تتضمن التركيبات بروتين دمج fusion protein يتضمن: (أ) بولي ببتيد polypeptide أول يتضمن إنترليوكين-2 Interleukin-2 (IL-2) أو صورة مختلفة أو شظية وظيفية functional fragment منه؛ و(ب) بولي ببتيد ثاني، مدمج في إطار بالبولي الببتيد الأول، حيث يتضمن البولي ببتيد الثاني نطاق خارج خلوي extracellular domain من المستقبل ألفا لإنترليوكين-2 Interleukin-2 Receptor alpha (IL-2Rα) أو صورة مختلفة أو شظية وظيفية منه، وحيث يتضمن بروتين الدمج نشاط إنترليوكين-2. تم توفير العديد من الطرق لتضمين الاستجابة المناعية immune response في خاضع تتضمن إعطاء الخاضع المحتاج مقدار فعال علاجيا من بروتين دمج إنترليوكين-2/المستقبل ألفا لإنترليوكين-2 المكشوف عنه هنا. شكل 6
SA517380842A 2014-08-06 2017-02-05 بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام SA517380842B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
SA517380842B1 true SA517380842B1 (ar) 2021-12-26

Family

ID=53836871

Family Applications (1)

Application Number Title Priority Date Filing Date
SA517380842A SA517380842B1 (ar) 2014-08-06 2017-02-05 بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام

Country Status (32)

Country Link
US (2) US12084483B2 (ar)
EP (2) EP4438621A3 (ar)
JP (3) JP6723982B2 (ar)
KR (1) KR102653758B1 (ar)
CN (2) CN113912737A (ar)
AU (3) AU2015301071C1 (ar)
BR (1) BR112017001940A2 (ar)
CA (1) CA2957273C (ar)
CL (1) CL2017000284A1 (ar)
CO (1) CO2017002166A2 (ar)
DK (1) DK3177307T3 (ar)
EA (2) EA202091342A3 (ar)
ES (1) ES2986097T3 (ar)
FI (1) FI3177307T3 (ar)
HR (1) HRP20241258T1 (ar)
HU (1) HUE068478T2 (ar)
IL (2) IL250007B (ar)
LT (1) LT3177307T (ar)
MA (2) MA40094B1 (ar)
MX (1) MX2017001062A (ar)
MY (1) MY180831A (ar)
PE (1) PE20170503A1 (ar)
PH (1) PH12017500042A1 (ar)
PT (1) PT3177307T (ar)
RS (1) RS65930B1 (ar)
SA (1) SA517380842B1 (ar)
SG (2) SG11201700706WA (ar)
SI (1) SI3177307T1 (ar)
SM (1) SMT202400414T1 (ar)
TN (1) TN2017000020A1 (ar)
WO (1) WO2016022671A1 (ar)
ZA (1) ZA201700245B (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
UA120847C2 (uk) 2014-02-06 2020-02-25 Ф. Хоффманн-Ля Рош Аг Злитий білок інтерлейкіну-2 і його застосування
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
EP3746103A4 (en) * 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US20210015864A1 (en) * 2018-03-23 2021-01-21 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CA3094112A1 (en) * 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
JP2022525921A (ja) * 2019-03-18 2022-05-20 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー 免疫エフェクタ細胞の特異的活性化のためのインターロイキン２受容体（ｉｌ２ｒ）およびインターロイキン２（ｉｌ２）バリアント
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
AU2020285636A1 (en) * 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
CN114450297A (zh) * 2019-07-12 2022-05-06 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
JP2022542886A (ja) * 2019-07-25 2022-10-07 ザ・ユニバーシティ・オブ・シカゴ プロテアーゼ活性化治療剤を含む組成物および方法
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
KR20220084066A (ko) * 2019-10-18 2022-06-21 엘커메스 파마 아일랜드 리미티드 면역 체크포인트 억제제와 조합된 면역조절성 il-2 제제
CN115023444A (zh) 2019-12-20 2022-09-06 再生元制药公司 新型il2激动剂及其使用方法
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
EP4475865A2 (en) * 2022-02-11 2024-12-18 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy
WO2023159135A2 (en) * 2022-02-16 2023-08-24 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
WO2024175020A1 (en) * 2023-02-22 2024-08-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-il2ra antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
ES2196098T3 (es) * 1994-12-28 2003-12-16 Univ Kentucky Res Found Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
WO2003029475A1 (en) * 2001-09-28 2003-04-10 Dnavec Research Inc. MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF
BRPI0508470A (pt) 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
US8124084B2 (en) 2005-05-17 2012-02-28 University Of Connecticut Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
US8734774B2 (en) * 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
JP6388408B2 (ja) 2012-06-08 2018-09-12 アルカーメス ファーマ アイルランド リミテッド アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
SG10201913695PA (en) 2020-03-30
CN107074967A (zh) 2017-08-18
EP3177307A1 (en) 2017-06-14
HRP20241258T1 (hr) 2024-12-06
ES2986097T3 (es) 2024-11-08
US12084483B2 (en) 2024-09-10
KR102653758B1 (ko) 2024-04-04
EA202091342A3 (ru) 2020-12-30
AU2015301071A1 (en) 2017-02-02
SG11201700706WA (en) 2017-02-27
EA035956B1 (ru) 2020-09-04
IL275944A (en) 2020-08-31
EP3177307B1 (en) 2024-07-17
US20230079120A1 (en) 2023-03-16
MA40721A (fr) 2017-06-13
MY180831A (en) 2020-12-10
MA40094B1 (fr) 2022-05-31
RS65930B1 (sr) 2024-10-31
PT3177307T (pt) 2024-09-13
EP4438621A3 (en) 2024-12-18
EA202091342A2 (ru) 2020-11-30
PE20170503A1 (es) 2017-05-11
MX2017001062A (es) 2017-07-14
US20170233448A1 (en) 2017-08-17
WO2016022671A1 (en) 2016-02-11
CN107074967B (zh) 2021-06-08
IL250007B (en) 2020-07-30
IL250007A0 (en) 2017-03-30
HUE068478T2 (hu) 2025-01-28
EA201790063A1 (ru) 2017-06-30
AU2020203352B2 (en) 2022-03-10
CN113912737A (zh) 2022-01-11
CO2017002166A2 (es) 2017-05-19
JP7272663B2 (ja) 2023-05-12
LT3177307T (lt) 2024-08-12
TN2017000020A1 (en) 2018-07-04
SMT202400414T1 (it) 2024-11-15
MA40721B1 (fr) 2024-08-30
NZ766851A (en) 2024-07-26
ZA201700245B (en) 2024-06-26
JP2017523789A (ja) 2017-08-24
AU2022204034A1 (en) 2022-07-14
NZ728042A (en) 2024-07-26
AU2015301071B2 (en) 2020-03-05
AU2020203352A1 (en) 2020-07-02
PH12017500042A1 (en) 2017-05-22
JP6723982B2 (ja) 2020-07-15
JP2021000084A (ja) 2021-01-07
DK3177307T3 (da) 2024-10-07
JP2023099045A (ja) 2023-07-11
KR20170030646A (ko) 2017-03-17
IL275944B (en) 2022-02-01
FI3177307T3 (fi) 2024-10-04
CL2017000284A1 (es) 2017-11-17
BR112017001940A2 (pt) 2017-11-28
AU2015301071C1 (en) 2020-07-02
MA40094A1 (fr) 2021-09-30
CA2957273A1 (en) 2016-02-11
CA2957273C (en) 2023-03-14
EP4438621A2 (en) 2024-10-02
SI3177307T1 (sl) 2024-09-30

Similar Documents

Publication Publication Date Title
SA517380842B1 (ar) بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PH12018501882A1 (en) Binding proteins and methods of use thereof
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
UY36021A (es) Proteìnas fc multimèricas
EP4223784A3 (en) Compositions and methods for modulating t-cell mediated immune response
EA201591331A1 (ru) Антагонисты il-33 и их применение
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX377091B (es) Proteina anti-garp y sus usos.
IL275779A (en) Recombinant human sialidases, sialidase-related proteins and methods of using them
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2019012419A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
MY191217A (en) Group a streptococcus vaccine
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
TH1701000601A (th) ฟิวชันโปรตีนของอินเตอร์ลูคิน-2/อินเตอร์ลูคิน-2 รีเซปเตอร์แอลฟา และวิธีการใช้
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
TH1501005499A (th) โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้
RU2013131997A (ru) НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2)